Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2015, Vol. 20 ›› Issue (1): 106-111.
Previous Articles Next Articles
ZHANG Zhe, SUN Li, YUAN Sheng-tao
Received:
2013-11-25
Revised:
2014-10-07
Published:
2020-07-20
CLC Number:
ZHANG Zhe, SUN Li, YUAN Sheng-tao. Progress on researches for topotecan in combination drug therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 106-111.
[1] 范岚, 谢海棠, 周宏灏. 中西药合用治疗肿瘤的相互作用及其机制探讨[J]. 中国临床药理学与治疗学, 2007, 12(2): 134-139. [2] Dennis MJ, Beijnen JH. An Overview of the clinical pharmacology of topotecan[J]. Semin Oncol, 1997, 24(Suppl 5): 12-18. [3] Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond[J]. Nat Rev Cancer, 2006, 6(10): 789-802. [4] Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. Nat Cancer Inst, 1996, 88: 734. [5] Köcher S, Spies-Naumann A, Kriegs M, et al. ATM is required for the repair of Topotecan-induced replication-associated double-strand breaks[J]. Radiother Oncol, 2013, 108(3): 409-414. [6] Ge XH, Lin Q, Ren XC, et al. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer[J]. Radiat Oncol, 2013, 8(1): 238/1-238/11. [7] Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer[J]. Gynecol Oncol, 2001, 83(2): 257-262. [8] Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway[J]. Int J Cancer, 2002, 98(1): 36-41. [9] Calvani M, Rapisarda A, Uranchimeg B, et al. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells[J]. Blood, 2006, 107(7): 2705-2712. [10] Zhou LQ, Sun L, Zhu DN, et al. Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan[J]. Med Oncol, 2011, 28(Suppl 1): S653-S659. [11] Puppo M, Battaglia F, Ottaviano C, et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha[J]. Mol Cancer Ther, 2008, 7(7): 1974-1984. [12] Lin SS, Sun L, Zhang YK, et al. Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases[J]. Acta Pharmacol Sin, 2009, 30(5): 628-636. [13] Musa F, Blank S, Muggia F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy[J]. Expert Opin Drug Metab Toxicol, 2013, 9(2): 215-224. [14] Levy B, Saxena A, Schneider BJ. Systemic therapy for small cell lung cancer[J]. Natl Compr Canc Netw, 2013, 11(7):780-787. [15] 史惠蓉, 侯丽娟, 乔玉环,等. 顺铂及拓扑替康对卵巢癌裸鼠移植瘤生长的抑制作用[J]. 郑州大学学报, 2004, 39(4): 563-565. [16] Manci N, Marchetti C, Benedetti Panici P, et al. A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer[J]. Gynecol Oncol, 2011, 122(2): 285-290. [17] Rose PG, Sill MW, Fracasso PM, et al. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study[J]. Gynecol Oncol, 2012, 125(1): 158-162. [18] Hosomi Y, Shibuya M, Watanabe K, et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer[J]. Anticancer Res, 2011, 31(10): 3449-3456. [19] Ramasubbaiah R, Perkins SM, Sutton G, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group[J]. Gynecol Oncol, 2011, 123(3): 499-504. [20] Ortholan C, Durivault J, Hannoun-Levi JM, et al. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment[J]. Eur J Cancer, 2010, 46(16): 3022-3036. [21] McGonigle KF, Muntz HG, Malpass TW, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study[J]. Cancer, 2011, 117(16): 3731-3740. [22] Powell SF, Beitinjaneh A, Tessema M, et al. Phase II study of topotecan and bevacizumab in advanced, refractory non-small-cell lung cancer[J]. Clin Lung Cancer, 2013, 14(5): 495-501. [23] Spigel DR, Waterhouse DM, Lane S, et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell Lung cancer: An open-label multicenter single-arm phase II study[J]. Clin Lung Cancer, 2013, 14(4): 356-363. [24] Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific[J]. J Thorac Oncol, 2007, 2(2): 160-165. [25] Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011, 29(3): 287-293. [26] Nogami N, Hotta K, Tanimoto M, et al. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401[J]. Lung Cancer, 2011, 74(1): 80-84. [27] Burris HA, Infante JR, Jewell RC, et al. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies[J]. Oncologist, 2010, 15(9): 954-960. [28] Serna DS, Bekaii-Saab T, Kraut EH. A phase I study of topotecan and gemcitabine in advanced solid tumors[J]. Invest New Drugs, 2011, 29(6): 1390-1394. [29] Joly F, Petit T, Pautier P, et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study[J]. Gynecol Oncol, 2009, 115(3): 382-388. [30] Gupta D, Owers RL, Kim M, et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers[J]. Gynecol Oncol,2009, 113(3): 327-330. [31] Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity[J]. Cancer, 2012, 118(22): 5663-5670. [32] Ashraf K, Shaikh F, Gibson P, et al. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma[J]. Pediatr Blood Cancer, 2013, 60(10): 1636-1641. [33] Blanchette P, Hogg D, Ferguson P, et al. Topotecan and cyclophosphamide in adults with relapsed sarcoma[J]. Sarcoma, 2012, 2012: 749067. [34] Kebudi R, Cakir FB, Gorgun O, et al. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors[J]. Pediatr Hematol Oncol, 2013, 30(3): 170-177. [35] Li N, Song Y, Du P, et al. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers[J]. Biomed Pharmacother,2013, 67(8): 801-806. [36] Turner DC, Tillmanns TD, Harstead KE, et al. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer[J]. Anticancer Res, 2013, 33(9): 3823-3829. [37] Patankar NA, Pritchard J, van Grinsven M, et al. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity[J]. Clin Cancer Res, 2013, 19(4): 865-877. [38] Kumar S, Mokhtari RB, Oliveira ID, et al. Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts[J]. Transl Oncol, 2013, 6(4): 493-503. |
[1] | LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577. |
[2] | LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444. |
[3] | WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454. |
[4] | LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340. |
[5] | WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234. |
[6] | ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153. |
[7] | LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176. |
[8] | LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9. |
[9] | HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50. |
[10] | GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85. |
[11] | LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92. |
[12] | HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100. |
[13] | WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960. |
[14] | SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574. |
[15] | MA Wangbo, Ma Yue, FAN Fangtian, ZHANG Yuhan, CHANG Jingwen, ZHOU Zhihua. Effects of Shenqi fuzheng injection on low-glucose-mediated immunosuppressive microenvironment and its mechanism of action [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 136-143. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||